Management of polycythaemia vera: A critical review of current data

British Journal of Haematology

Volumn 172, Issue 3, 2016, Pages 337-349

  Mcmullin, Mary F ^a   Wilkins, Bridget S ^b   Harrison, Claire N ^b  

^a QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

^b GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

JAK2; Myeloproliferative; Polycythaemia vera

Indexed keywords

ACETYLSALICYLIC ACID; ANAGRELIDE; BUSULFAN; GIVINOSTAT; HYDROXYUREA; MOMELOTINIB; PACRITINIB; PEGINTERFERON ALPHA; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; PHOSPHORUS 32; PIPOBROMAN; PLACEBO; RUXOLITINIB; VORINOSTAT; JAK2 PROTEIN, HUMAN; JANUS KINASE 2; PROTEIN KINASE INHIBITOR; PYRAZOLE DERIVATIVE;

ACUTE LEUKEMIA; ACUTE MYELOBLASTIC LEUKEMIA; BLEEDING; BLOOD TOXICITY; CANCER MORTALITY; DEEP VEIN THROMBOSIS; DIET SUPPLEMENTATION; DISEASE COURSE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; HEART INFARCTION; HERPES ZOSTER; HIGH RISK POPULATION; HUMAN; LIFE EXPECTANCY; LUNG EMBOLISM; MONOTHERAPY; MYELOFIBROSIS; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHLEBOTOMY; POLYCYTHEMIA VERA; PORTAL VEIN THROMBOSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SPLEEN INFARCTION; SURVIVAL RATE; THROMBOEMBOLISM; THROMBOPHLEBITIS; THROMBOSIS; TREATMENT INDICATION; TREATMENT RESPONSE; TREATMENT WITHDRAWAL; UNSPECIFIED SIDE EFFECT; ANTAGONISTS AND INHIBITORS; DISEASE MANAGEMENT; DRUG RESISTANCE; GENETICS; RISK FACTOR;

DISEASE MANAGEMENT; DRUG RESISTANCE; HUMANS; HYDROXYUREA; JANUS KINASE 2; POLYCYTHEMIA VERA; PROTEIN KINASE INHIBITORS; PYRAZOLES; RISK FACTORS;

EID: 84955736404     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/bjh.13812     Document Type: Review

References (62)

1. Alvarez-Larran, A., Pereira, A., Cervantes, F., Arellano-Rodrigo, E., Hernández-Boluda, J.C., Ferrer-Marín, F., Angona, A., Gómez, M., Muiña, B., Guillén, H., Teruel, A., Bellosillo, B., Burgaleta, C., Vicente, V. & Besses, C. (2012) Assessment and prognostic value of the European LeukemiaNet criteria for clinicohematologic response, resistance, and intolerance to hydroxyurea in polycythemia vera. Blood, 119, 1363-1369.
2. Alvarez-Larran, A., Ancochea, A., Garcia, M., Climent, F., Garcia-Pallarols, F., Angona, A., Senin, A., Barranco, C., Martinez-Aviles, L., Serrano, S., Bellosillo, B. & Besses, C. (2014a) WHO-histological criteria for myeloproliferative neoplasms: reproducibility, diagnostic accuracy and correlation with gene mutations and clinical outcomes. British Journal of Haematology, 166, 911-919.
3. Alvarez-Larran, A., Martinez-Aviles, L., Hernandez-Boluda, J.C., Ferrer-Marin, F., Antelo, M.L., Burgaleta, C., Mata, M.I., Xicoy, B., Martinez-Trillos, A., Gomez-Casares, M.T., Duran, M.A., Marcote, B., Ancochea, A., Senin, A., Angona, A., Gomez, M., Vicente, V., Cervantes, F., Bellosillo, B. & Besses, C. (2014b) Busulfan in patients with polycythemia vera or essential thrombocythemia refractory or intolerant to hydroxyurea. Annals of Hematology, 93, 2037-2043.
4. Alvarez-Larran, A., Angona, A., Ancochea, A., Garcia-Pallarols, F., Fernandez, C., Longaron, R., Bellosillo, B. & Besses, C. (2015) Masked polycythaemia vera: presenting features, response to treatment and clinical outcomes. European Journal of Haematology. doi: 10.1111/ejh.12552 [Epub ahead of print].
5. Andersen, C.L., McMullin, M.F., Ejerblad, E., Zweegman, S., Harrison, C., Fernandes, S., Bareford, D., Knapper, S., Samuelsson, J., Lofvenberg, E., Linder, O., Andreasson, B., Ahlstrand, E., Jensen, M.K., Bjerrum, O.W., Vestergaard, H., Larsen, H., Klausen, T.W., Mourits-Andersen, T. & Hasselbalch, H.C. (2013) A phase II study of vorinostat (MK-0683) in patients with polycythaemia vera and essential thrombocythaemia. British Journal of Haematology, 162, 498-508.
6. Barbui, T., Barosi, G., Birgegard, G., Cervantes, F., Finazzi, G., Griesshammer, M., Harrison, C., Hasselbalch, H.C., Hehlmann, R., Hoffman, R., Kiladjian, J.J., Kroger, N., Mesa, R., McMullin, M.F., Pardanani, A., Passamonti, F., Vannucchi, A.M., Reiter, A., Silver, R.T., Verstovsek, S. & Tefferi, A. (2011) Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet. Journal of Clinical Oncology, 29, 761-770.
7. Barbui, T., Thiele, J., Passamonti, F., Rumi, E., Boveri, E., Randi, M.L., Bertozzi, I., Marino, F., Vannucchi, A.M., Pieri, L., Rotunno, G., Gisslinger, H., Gisslinger, B., Mullauer, L., Finazzi, G., Carobbio, A., Gianatti, A., Ruggeri, M., Nichele, I., D'Amore, E., Rambaldi, A. & Tefferi, A. (2012) Initial bone marrow reticulin fibrosis in polycythemia vera exerts an impact on clinical outcome. Blood, 119, 2239-2241.
8. Barbui, T., Thiele, J., Carobbio, A., Gisslinger, H., Finazzi, G., Rumi, E., Luigia Randi, M., Vannucchi, A.M., Gisslinger, B., Mullauer, L., Ruggeri, M., Rambaldi, A. & Tefferi, A. (2014a) Masked polycythemia vera diagnosed according to WHO and BCSH classification. American Journal of Hematology, 89, 199-202.
9. Barbui, T., Thiele, J., Carobbio, A., Guglielmelli, P., Rambaldi, A., Vannucchi, A.M. & Tefferi, A. (2014b) Discriminating between essential thrombocythemia and masked polycythemia vera in JAK2 mutated patients. American Journal of Hematology, 89, 588-590.
10. Barbui, T., Thiele, J., Vannucchi, A.M. & Tefferi, A. (2014c) Rethinking the diagnostic criteria of polycythemia vera. Leukemia, 28, 1191-1195.
11. Barosi, G., Mesa, R.A., Thiele, J., Cervantes, F., Campbell, P.J., Verstovsek, S., Dupriez, B., Levine, R.L., Passamonti, F., Gotlib, J., Reilly, J.T., Vannucchi, A.M., Hanson, C.A., Solberg, L.A., Orazi, A., Tefferi, A. & International Working Group for Myelofibrosis Research and Treatment (IWG-MRT). (2008a) Proposed criteria for the diagnosis of post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a consensus statement from the International Working Group for Myelofibrosis Research and Treatment. Leukemia, 22, 437-438.
12. Barosi, G., Mesa, R.A., Thiele, J., Cervantes, F., Campbell, P.J., Verstovsek, S., Dupriez, B., Levine, R.L., Passamonti, F., Gotlib, J., Reilly, J.T., Vannucchi, A.M., Hanson, C.A., Solberg, L.A., Orazi, A. & Tefferi, A. (2008b) Proposed criteria for the diagnosis of post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a consensus statement from the International Working Group for Myelofibrosis Research and Treatment. Leukemia, 22, 437-438.
13. Barosi, G., Birgegard, G., Finazzi, G., Griesshammer, M., Harrison, C., Hasselbalch, H.C., Kiladjian, J.J., Lengfelder, E., McMullin, M.F., Passamonti, F., Reilly, J.T., Vannucchi, A.M. & Barbui, T. (2009) Response criteria for essential thrombocythemia and polycythemia vera: result of a European LeukemiaNet consensus conference. Blood, 113, 4829-4833.
14. Barosi, G., Birgegard, G., Finazzi, G., Griesshammer, M., Harrison, C., Hasselbalch, H., Kiladijan, J.J., Lengfelder, E., Mesa, R., Mc Mullin, M.F., Passamonti, F., Reilly, J.T., Vannucchi, A.M. & Barbui, T. (2010) A unified definition of clinical resistance and intolerance to hydroxycarbamide in polycythaemia vera and primary myelofibrosis: results of a European LeukemiaNet (ELN) consensus process. British Journal of Haematology, 148, 961-963.
15. Barosi, G., Mesa, R., Finazzi, G., Harrison, C., Kiladjian, J.J., Lengfelder, E., McMullin, M.F., Passamonti, F., Vannucchi, A.M., Besses, C., Gisslinger, H., Samuelsson, J., Verstovsek, S., Hoffman, R., Pardanani, A., Cervantes, F., Tefferi, A. & Barbui, T. (2013) Revised response criteria for polycythemia vera and essential thrombocythemia: an ELN and IWG-MRT consensus project. Blood, 121, 4778-4781.
16. Baxter, E.J., Scott, L.M., Campbell, P.J., East, C., Fourouclas, N., Swanton, S., Vassiliou, G.S., Bench, A.J., Boyd, E.M., Curtin, N., Scott, M.A., Erber, W.N. & Green, A.R. (2005) Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet, 365, 1054-1061.
17. Campbell, P.J., Scott, L.M., Buck, G., Wheatley, K., East, C.L., Marsden, J.T., Duffy, A., Boyd, E.M., Bench, A.J., Scott, M.A., Vassiliou, G.S., Milligan, D.W., Smith, S.R., Erber, W.N., Bareford, D., Wilkins, B.S., Reilly, J.T., Harrison, C.N. & Green, A.R. (2005) Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: a prospective study. Lancet, 366, 1945-1953.
18. Cervantes, F. (2014) How I treat myelofibrosis. Blood, 124, 2635-2642.
19. Chievitz, E. & Thiede, T. (1962) Complications and causes of death in polycythaemia vera. Acta Medica Scandinavica, 172, 513-523.
20. Dameshek, W. (1951) Some speculations on the myeloproliferative syndromes. Blood, 6, 372-375.
21. Emanuel, R.M., Dueck, A.C., Geyer, H.L., Kiladjian, J.J., Slot, S., Zweegman, S., te Boekhorst, P.A., Commandeur, S., Schouten, H.C., Sackmann, F., Kerguelen Fuentes, A., Hernández-Maraver, D., Pahl, H.L., Griesshammer, M., Stegelmann, F., Doehner, K., Lehmann, T., Bonatz, K., Reiter, A., Boyer, F., Etienne, G., Ianotto, J.C., Ranta, D., Roy, L., Cahn, J.Y., Harrison, C.N., Radia, D., Muxi, P., Maldonado, N., Besses, C., Cervantes, F., Johansson, P.L., Barbui, T., Barosi, G., Vannucchi, A.M., Passamonti, F., Andreasson, B., Ferrari, M.L., Rambaldi, A., Samuelsson, J., Birgegard, G., Tefferi, A. & Mesa, R.A. (2012) Myeloproliferative neoplasm (MPN) symptom assessment form total symptom score: prospective international assessment of an abbreviated symptom burden scoring system among patients with MPNs. Journal of Clinical Oncology, 30, 4098-4103.
22. Finazzi, G., Caruso, V., Marchioli, R., Capnist, G., Chisesi, T., Finelli, C., Gugliotta, L., Landolfi, R., Kutti, J., Gisslinger, H., Marilus, R., Patrono, C., Pogliani, E.M., Randi, M.L., Villegas, A., Tognoni, G. & Barbui, T. (2005) Acute leukemia in polycythemia vera: an analysis of 1638 patients enrolled in a prospective observational study. Blood, 105, 2664-2670.
23. Finazzi, G., Vannucchi, A.M., Martinelli, V., Ruggeri, M., Nobile, F., Specchia, G., Pogliani, E.M., Olimpieri, O.M., Fioritoni, G., Musolino, C., Cilloni, D., Sivera, P., Barosi, G., Finazzi, M.C., Di Tollo, S., Demuth, T., Barbui, T. & Rambaldi, A. (2013) A phase II study of Givinostat in combination with hydroxycarbamide in patients with polycythaemia vera unresponsive to hydroxycarbamide monotherapy. British Journal of Haematology, 161, 688-694.
24. Gangat, N., Strand, J., Li, C.Y., Wu, W., Pardanani, A. & Tefferi, A. (2007) Leucocytosis in polycythaemia vera predicts both inferior survival and leukaemic transformation. British Journal of Haematology, 138, 354-358.
25. Gangat, N., Wolanskyj, A.P., Schwager, S.M., Hanson, C.A. & Tefferi, A. (2009) Leukocytosis at diagnosis and the risk of subsequent thrombosis in patients with low-risk essential thrombocythemia and polycythemia vera. Cancer, 115, 5740-5745.
26. Geyer, H. & Mesa, R.A. (2014) Assessing disease burden in patients with classic MPNs. Best Practice & Research. Clinical Haematology, 27, 107-119.
27. Gowin, K., Verstovsek, S., Daver, N., Pemmaraju, N., Valdez, R., Kosiorek, H., Dueck, A. & Mesa, R. (2015) Limitations of fibrosis grade as diagnostic criteria for post polycythemia vera and essential thrombocytosis myelofibrosis. Leukemia Research, 39, 684-688.
28. Harrison, C.N., Campbell, P.J., Buck, G., Wheatley, K., East, C.L., Bareford, D., Wilkins, B.S., van der Walt, J.D., Reilly, J.T., Grigg, A.P., Revell, P., Woodcock, B.E., Green, A.R. & United Kingdom Medical Research Council Primary Thrombocythemia 1 Study. (2005) Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia. The New England Journal of Medicine, 353, 33-45.
29. Hernandez-Boluda, J.C., Alvarez-Larran, A., Gomez, M., Angona, A., Amat, P., Bellosillo, B., Martinez-Aviles, L., Navarro, B., Teruel, A., Martinez-Ruiz, F. & Besses, C. (2011) Clinical evaluation of the European LeukaemiaNet criteria for clinicohaematological response and resistance/intolerance to hydroxycarbamide in essential thrombocythaemia. British Journal of Haematology, 152, 81-88.
30. Hultcrantz, M., Kristinsson, S.Y., Andersson, T.M., Landgren, O., Eloranta, S., Derolf, A.R., Dickman, P.W. & Bjorkholm, M. (2012) Patterns of survival among patients with myeloproliferative neoplasms diagnosed in Sweden from 1973 to 2008: a population-based study. Journal of Clinical Oncology, 30, 2995-3001.
31. James, C., Ugo, V., Le Couedic, J.P., Staerk, J., Delhommeau, F., Lacout, C., Garcon, L., Raslova, H., Berger, R., Bennaceur-Griscelli, A., Villeval, J.L., Constantinescu, S.N., Casadevall, N. & Vainchenker, W. (2005) A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature, 434, 1144-1148.
32. Johansson, P.L., Safai-Kutti, S. & Kutti, J. (2005) An elevated venous haemoglobin concentration cannot be used as a surrogate marker for absolute erythrocytosis: a study of patients with polycythaemia vera and apparent polycythaemia. British Journal of Haematology, 129, 701-705.
33. Jones, A.V., Silver, R.T., Waghorn, K., Curtis, C., Kreil, S., Zoi, K., Hochhaus, A., Oscier, D., Metzgeroth, G., Lengfelder, E., Reiter, A., Chase, A.J. & Cross, N.C. (2006) Minimal molecular response in polycythemia vera patients treated with imatinib or interferon alpha. Blood, 107, 3339-3341.
34. Kiladjian, J.J., Cassinat, B., Chevret, S., Turlure, P., Cambier, N., Roussel, M., Bellucci, S., Grandchamp, B., Chomienne, C. & Fenaux, P. (2008) Pegylated interferon-alfa-2a induces complete hematologic and molecular responses with low toxicity in polycythemia vera. Blood, 112, 3065-3072.
35. Kiladjian, J.J., Masse, A., Cassinat, B., Mokrani, H., Teyssandier, I., le Couedic, J.P., Cambier, N., Almire, C., Pronier, E., Casadevall, N., Vainchenker, W., Chomienne, C. & Delhommeau, F. (2010) Clonal analysis of erythroid progenitors suggests that pegylated interferon alpha-2a treatment targets JAK2V617F clones without affecting TET2 mutant cells. Leukemia, 24, 1519-1523.
36. Kiladjian, J.J., Chevret, S., Dosquet, C., Chomienne, C. & Rain, J.D. (2011) Treatment of polycythemia vera with hydroxyurea and pipobroman: final results of a randomized trial initiated in 1980. Journal of Clinical Oncology, 29, 3907-3913.
37. Kralovics, R., Passamonti, F., Buser, A.S., Teo, S.S., Tiedt, R., Passweg, J.R., Tichelli, A., Cazzola, M. & Skoda, R.C. (2005) A gain-of-function mutation of JAK2 in myeloproliferative disorders. The New England Journal of Medicine, 352, 1779-1790.
38. Landolfi, R., Marchioli, R., Kutti, J., Gisslinger, H., Tognoni, G., Patrono, C. & Barbui, T. (2004) Efficacy and safety of low-dose aspirin in polycythemia vera. The New England Journal of Medicine, 350, 114-124.
39. Landolfi, R., Di Gennaro, L., Barbui, T., De Stefano, V., Finazzi, G., Marfisi, R., Tognoni, G. & Marchioli, R. (2007) Leukocytosis as a major thrombotic risk factor in patients with polycythemia vera. Blood, 109, 2446-2452.
40. Levine, R.L., Wadleigh, M., Cools, J., Ebert, B.L., Wernig, G., Huntly, B.J., Boggon, T.J., Wlodarska, I., Clark, J.J., Moore, S., Adelsperger, J., Koo, S., Lee, J.C., Gabriel, S., Mercher, T., D'Andrea, A., Frohling, S., Dohner, K., Marynen, P., Vandenberghe, P., A. Mesa, R., Tefferi, A., Griffin, J.D., Eck, M.J., Sellers, W.R., Meyerson, M., Golub, T.R.S., Lee, J. & Gilliland, D.G. (2005) Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell, 7, 387-397.
41. Madelung, A.B., Bondo, H., Stamp, I., Loevgreen, P., Nielsen, S.L., Falensteen, A., Knudsen, H., Ehinger, M., Dahl-Sorensen, R., Mortensen, N.B., Svendsen, K.D., Lange, T., Ralfkiaer, E., Nielsen, K., Hasselbalch, H.C. & Thiele, J. (2013) World Health Organization-defined classification of myeloproliferative neoplasms: morphological reproducibility and clinical correlations - the Danish experience. American Journal of Hematology, 88, 1012-1016.
42. Marchioli, R., Finazzi, G., Landolfi, R., Kutti, J., Gisslinger, H., Patrono, C., Marilus, R., Villegas, A., Tognoni, G. & Barbui, T. (2005) Vascular and neoplastic risk in a large cohort of patients with polycythemia vera. Journal of Clinical Oncology, 23, 2224-2232.
43. Marchioli, R., Finazzi, G., Specchia, G., Cacciola, R., Cavazzina, R., Cilloni, D., De Stefano, V., Elli, E., Iurlo, A., Latagliata, R., Lunghi, F., Lunghi, M., Marfisi, R.M., Musto, P., Masciulli, A., Musolino, C., Cascavilla, N., Quarta, G., Randi, M.L., Rapezzi, D., Ruggeri, M., Rumi, E., Scortechini, A.R., Santini, S., Scarano, M., Siragusa, S., Spadea, A., Tieghi, A., Angelucci, E., Visani, G., Vannucchi, A.M. & Barbui, T. (2013) Cardiovascular events and intensity of treatment in polycythemia vera. The New England Journal of Medicine, 368, 22-33.
44. McMullin, M.F., Bareford, D., Campbell, P., Green, A.R., Harrison, C., Hunt, B., Oscier, D., Polkey, M.I., Reilly, J.T., Rosenthal, E., Ryan, K., Pearson, T.C. & Wilkins, B. (2005) Guidelines for the diagnosis, investigation and management of polycythaemia/erythrocytosis. British Journal of Haematology, 130, 174-195.
45. McMullin, M.F., Reilly, J.T., Campbell, P., Bareford, D., Green, A.R., Harrison, C.N., Conneally, E., National Cancer Research Institute, Myeloproliferative Disorder Subgroup, Ryan, K. & British Committee for Standards in Haematology. (2007) Amendment to the guideline for diagnosis and investigation of polycythaemia/erythrocytosis. British Journal of Haematology, 138, 821-822.
46. Mesa, R., Vannucchi, A.M., Yacoub, A., Zachee, P., Garg, M., Lyons, R., Chedid, S., Koschmieder, S., Rinaldi, C., Byrne, J., Hasan, Y., Passamonti, F., Verstovsek, S., Hunter, D., Jones, M.M., He, S., Morozov, A. & Martino, B. (2014) The efficacy and safety of continued hydroxyurea therapy versus switching to ruxolitinib in patients with polycythemia vera: a randomized, double-blind, double-dummy, symptom study (RELIEF). Blood (ASH Annual Meeting Abstracts), 124, 3168.
47. Ortmann, C.A., Kent, D.G., Nangalia, J., Silber, Y., Wedge, D.C., Grinfeld, J., Baxter, E.J., Massie, C.E., Papaemmanuil, E., Menon, S., Godfrey, A.L., Dimitropoulou, D., Guglielmelli, P., Bellosillo, B., Besses, C., Dohner, K., Harrison, C.N., Vassiliou, G.S., Vannucchi, A., Campbell, P.J. & Green, A.R. (2015) Effect of mutation order on myeloproliferative neoplasms. New England Journal of Medicine, 372, 601-612.
48. Passamonti, F., Rumi, E., Pietra, D., Elena, C., Boveri, E., Arcaini, L., Roncoroni, E., Astori, C., Merli, M., Boggi, S., Pascutto, C., Lazzarino, M. & Cazzola, M. (2010) A prospective study of 338 patients with polycythemia vera: the impact of JAK2 (V617F) allele burden and leukocytosis on fibrotic or leukemic disease transformation and vascular complications. Leukemia, 24, 1574-1579.
49. Pearson, T.C. & Messinezy, M. (1996) The diagnostic criteria of polycythaemia rubra vera. Leukemia & Lymphoma, 22, 87-93.
50. Pearson, T.C. & Wetherley-Mein, G. (1978) Vascular occlusive episodes and venous haematocrit in primary proliferative polycythaemia. Lancet, 2, 1219-1222.
51. Quintas-Cardama, A., Kantarjian, H., Manshouri, T., Luthra, R., Estrov, Z., Pierce, S., Richie, M.A., Borthakur, G., Konopleva, M., Cortes, J. & Verstovsek, S. (2009) Pegylated interferon alfa-2a yields high rates of hematologic and molecular response in patients with advanced essential thrombocythemia and polycythemia vera. Journal of Clinical Oncology, 27, 5418-5424.
52. Rambaldi, A., Dellacasa, C.M., Finazzi, G., Carobbio, A., Ferrari, M.L., Guglielmelli, P., Gattoni, E., Salmoiraghi, S., Finazzi, M.C., Di Tollo, S., D'Urzo, C., Vannucchi, A.M., Barosi, G. & Barbui, T. (2010) A pilot study of the Histone-Deacetylase inhibitor Givinostat in patients with JAK2V617F positive chronic myeloproliferative neoplasms. British Journal of Haematology, 150, 446-455.
53. Reilly, J.T., McMullin, M.F., Beer, P.A., Butt, N., Conneally, E., Duncombe, A.S., Green, A.R., Mikhaeel, G., Gilleece, M.H., Knapper, S., Mead, A.J., Mesa, R.A., Sekhar, M. & Harrison, C.N. (2014) Use of JAK inhibitors in the management of myelofibrosis: a revision of the British Committee for Standards in Haematology Guidelines for Investigation and Management of Myelofibrosis 2012. British Journal of Haematology, 167, 418-420.
54. Scherber, R.M., Geyer, H.L. & Mesa, R.A. (2014) Quality of life in MPN comes of age as a therapeutic target. Current Hematologic Malignancy Reports, 9, 324-330.
55. Scott, L.M., Tong, W., Levine, R.L., Scott, M.A., Beer, P.A., Stratton, M.R., Futreal, P.A., Erber, W.N., McMullin, M.F., Harrison, C.N., Warren, A.J., Gilliland, D.G., Lodish, H.F. & Green, A.R. (2007) JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis. The New England Journal of Medicine, 356, 459-468.
56. Silver, R.T., Kiladjian, J.J. & Hasselbalch, H.C. (2013) Interferon and the treatment of polycythemia vera, essential thrombocythemia and myelofibrosis. Expert Review of Hematology, 6, 49-58.
57. Sterkers, Y., Preudhomme, C., Lai, J.L., Demory, J.L., Caulier, M.T., Wattel, E., Bordessoule, D., Bauters, F. & Fenaux, P. (1998) Acute myeloid leukemia and myelodysplastic syndromes following essential thrombocythemia treated with hydroxyurea: high proportion of cases with 17p deletion. Blood, 91, 616-622.
58. Tefferi, A., Rumi, E., Finazzi, G., Gisslinger, H., Vannucchi, A.M., Rodeghiero, F., Randi, M.L., Vaidya, R., Cazzola, M., Rambaldi, A., Gisslinger, B., Pieri, L., Ruggeri, M., Bertozzi, I., Sulai, N.H., Casetti, I., Carobbio, A., Jeryczynski, G., Larson, D.R., Mullauer, L., Pardanani, A., Thiele, J., Passamonti, F. & Barbui, T. (2013) Survival and prognosis among 1545 patients with contemporary polycythemia vera: an international study. Leukemia, 27, 1874-1881.
59. Vannucchi, A.M., Kiladjian, J.J., Griesshammer, M., Masszi, T., Durrant, S., Passamonti, F., Harrison, C.N., Pane, F., Zachee, P., Mesa, R., He, S., Jones, M.M., Garrett, W., Li, J., Pirron, U., Habr, D. & Verstovsek, S. (2015) Ruxolitinib versus standard therapy for the treatment of polycythemia vera. New England Journal of Medicine, 372, 426-435.
60. Vaquez, H. (1892) Sur une forme speciale de cyanose s'accompanant d'hyperglobulie excessive et peristente [On a special form of cyanosis accompanied by excessive and persistent erythrocytosis]. Compt rend Soc de biol and suppl note, Bull et mem Soc med d'hop de Paris, 44, 384-388.
61. Vardiman, J.W., Thiele, J., Arber, D.A., Brunning, R.D., Borowitz, M.J., Porwit, A., Harris, N.L., Le Beau, M.M., Hellstrom-Lindberg, E., Tefferi, A. & Bloomfield, C.D. (2009) The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood, 114, 937-951.
62. Verstovsek, S., Passamonti, F., Rambaldi, A., Barosi, G., Rosen, P.J., Rumi, E., Gattoni, E., Pieri, L., Guglielmelli, P., Elena, C., He, S., Contel, N., Mookerjee, B., Sandor, V., Cazzola, M., Kantarjian, H.M., Barbui, T. & Vannucchi, A.M. (2014) A phase 2 study of ruxolitinib, an oral JAK1 and JAK2 Inhibitor, in patients with advanced polycythemia vera who are refractory or intolerant to hydroxyurea. Cancer, 120, 513-520.